Cancer of Colon
38
2
5
21
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.3%
2 terminated out of 38 trials
91.3%
+4.8% vs benchmark
3%
1 trials in Phase 3/4
5%
1 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (38)
Getting To Implementation: Improving Cancer Screening for Veterans
Effect of Music Prehabilitation on Preoperative Anxiety Before Surgery
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
Evaluation of the Medical Service by Socio-aesthetics in Oncology
Tempus Priority Study: A Pan-tumor Observational Study
Abdominopelvic Cancer Prehabilitation
The Registry of Oncology Outcomes Associated with Testing and Treatment
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Immunologic Changes and Recovery-related Factors in Elderly Colon Cancer Patients
ExPECT: Extraperitoneal End Colostomy Trial
Impact of 5-Fluorouracil (5-FU) on Cancer Cells From Liver Metastases of Colon Cancer
Colorectal Health Research Champions
Anesthesia and Cancer Study: Colon Cancer
Clinical Trial Comparing Standard Care Versus Prehabilitation in Patients Undergoing Cancer Surgery
Developing and Evaluating Product Messaging
Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
Preoperative Immunonutrition in Patients Undergoing Elective Colorectal Surgery for Neoplasm
Integrative Nutrition Care Plan for the Patient With Liver and Colorectal Cancer
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)